Fulcrum Therapeutics (FULC) Profit After Tax (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Profit After Tax for 9 consecutive years, with -$26.2 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Profit After Tax fell 51.67% year-over-year to -$26.2 million; the TTM figure through Jun 2026 stood at -$85.1 million (down 15.36% YoY), while the FY2025 annual figure was -$74.9 million, down 669.97% from the prior year.
• Profit After Tax fell to -$26.2 million in Q2 2026 per FULC's latest filing, from -$18.9 million in the prior quarter.
• Across five years, Profit After Tax topped out at $55.4 million in Q2 2024 and bottomed at -$34.1 million in Q2 2022.
• Historically, Profit After Tax has averaged -$18.8 million across 5 years, with a median of -$23.8 million in 2022.
• Annual changes were most pronounced in 2024 — Profit After Tax soared 332.98% — and 2025, when it slumped 131.22%.
• Fulcrum Therapeutics' Profit After Tax stood at -$26.5 million in 2022, then climbed by 6.7% to -$24.8 million in 2023, then surged by 30.99% to -$17.1 million in 2024, then decreased by 19.03% to -$20.3 million in 2025, then decreased by 29.01% to -$26.2 million in 2026.
• Business Quant data shows FULC's Profit After Tax at -$26.2 million in Q2 2026, -$18.9 million in Q1 2026, and -$20.3 million in Q4 2025.